← All companies

ZYBT

Zhengye Biotechnology Holding Limited

ZYBT Nasdaq Pharmaceutical Preparations EDGAR ↗

$1.33

+0.00 0.00%

Key statistics

from XBRL data in SEC filings

Market cap

$63.0M

Revenue (TTM)

$16.6M

Net income (TTM)

-$9.98M

EPS (TTM)

$0.03

P/E ratio

44.3

Dividend yield

15413533.83%

Free cash flow

$1.77M

Cash

$7.20M

Total assets

$62.4M

Gross margin

20.5%

52-week range

$0.62 – $13.08

Recent SEC filings

40 most recent

Annual, quarterly & current reports

6-K REPORT OF FOREIGN PRIVATE ISSUER Jul 21, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Jun 4, 2026 20-F ANNUAL REPORT Apr 28, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 25, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 2, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Feb 23, 2026 6-K REPORT OF FOREIGN PRIVATE ISSUER Dec 12, 2025 20-F ANNUAL REPORT Jul 3, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER May 23, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER Apr 3, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER Mar 6, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER Jan 14, 2025 6-K REPORT OF FOREIGN PRIVATE ISSUER Jan 8, 2025

Other filings

3 Jun 25, 2026 3 Jun 25, 2026 3 Jun 25, 2026 3 Jun 25, 2026 3 Jun 25, 2026 3 Apr 24, 2026 3 Apr 24, 2026 3 Mar 18, 2026 3 Mar 18, 2026 3 Mar 18, 2026 3 Mar 18, 2026 144 Oct 22, 2025 144 Oct 22, 2025 NT 20-F NOTIFICATION OF LATE FILING Apr 29, 2025 SCHEDULE 13G Feb 21, 2025 424B4 PROSPECTUS Jan 7, 2025 CERT Jan 6, 2025 EFFECT Dec 20, 2024 8-A12B FOR REGISTRATION OF CERTAIN CLASSES Dec 19, 2024 POS AM POST-EFFECTIVE AMENDMENT Dec 9, 2024 FWP FREE WRITING PROSPECTUS Nov 21, 2024 POS AM POST-EFFECTIVE AMENDMENT Nov 15, 2024 EFFECT Item F-1; Item 2024-09-30; Item 16:30:00 Sep 30, 2024 CORRESP Sep 26, 2024 CORRESP Sep 26, 2024 F-1/A REGISTRATION STATEMENT Sep 18, 2024 FWP FREE WRITING PROSPECTUS Aug 27, 2024